Background A multicenter phase II trial was initiated to investigate the efficacy and tolerance of a dose-fractionated administration schedule of irinotecan in patients with advanced colorectal cancer pre-treated with fluoropyrimidine/ oxaliplatin-based first-line combination chemotherapy.
Introduction
Many patients with advanced colorectal cancer are candidates for additional chemotherapeutic measures after failure of fluoropyrimidine-based chemotherapy, because virtually all of them will experience disease progression after only a few months Until recently, these patients had few options, but now, apart from regional treatments in case of selective liver metastases, several different new drugs and systemic chemotherapy regimens exist [1] . The topoisomerase I inhibitor irinotecan, which in Europe is usually administered as a 90-min infusion at 350 mg/m 2 every three weeks, has been proven to be of particular value in this treatment setting: because of a significant survival advantage and a clinical benefit when compared to best supportive care alone or continuous infusional 5-fluorouracil (5-FU), its use as single agent is now considered standard second-line and new reference therapy for forthcoming clinical trials [2, 3] . The survival gain in the latter two studies, however, was only 2.3 and 2.7 months compared to the control arm; this modest benefit along with the rather high costs of treatment, and the fact that irinotecan can be associated with significant toxicity (the frequency of treatmentrelated hospital admissions in the two studies was as high as 69% and 72%, respectively) have been impediments to its universal adoption [4] . Therefore, modulations of the classical irinotecan regimen that can decrease the systemic toxicity while maintaining or even improving its antitumour efficacy would clearly be of interest. Preliminary results of various studies evaluating different administration schedules of irinotecan in patients with advanced colorectal cancer, in fact, seem to indicate that the therapeutic index can be improved [5] [6] [7] [8] . In a randomised four-arm trial, there was some evidence that biweekly administration of 250 mg/m 2 irinotecan will result in a lower rate of nausea, vomiting, and (febrile) neutropenia [5] . Similarly, preliminary results of a recently conducted randomised phase II study suggested that administration of the 350 mg/m 2 standard total dose fractionated into two doses every 21 days yields similar efficacy but a much lower incidence of toxicity than the classic schedule of the topoisomerase I inhibitor [6] The aim of the present multicenter phase II study was to try to confirm the latter encouraging findings in a different national setting involving a larger study population, and to investigate the therapeutic potential of this dose fractionated schedule in patients who had failed first-line oxaliplatin combination chemotherapy.
Patients and methods

Patient selection
Patients with histologically confirmed metastatic colorectal cancer and bidimensionally measurable disease were considered candidates for this study All patients must have developed progressive disease (PD) while receiving or within six months after discontinuing palliative oxahplatin-based chemotherapy Eligibility criteria also included age between 19 and 75 years, a World Health Organisation (WHO) performance status of 0 to 2, adequate bone marrow reserve (leukocyte count >4000/ul, platelet count > 100,000/ul), renal (serum creatimne concentration < 132 umol/l), and hepatic function (serum bilirubin and transaminase level <2 the upper limit of normal) Prior radiation therapy with at least one target lesion outside the radiation port was allowed Similarly, adjuvant treatment was acceptable if the time interval between adjuvant therapy and the chemotherapy for metastatic disease was longer than one year Exclusion criteria included the presence of CNS mctastases, serious or uncontrolled concurrent medical illness, and a history of other malignancies Informed consent according to institutional regulations was obtained from all patients prior to study entry Treatment plan Chemotherapy consisted of lnnotecan 175 mg/m 2 administered as a 90 min intravenous infusion on days 1 and 10 Treatment courses were repeated every three weeks for a total of six courses unless prior evidence of PD Concomitant medications routinely given before cytotoxic drug administration included 8 mg ondansetron and 8 mg dexamethasone
In the event of WHO grade 4 haematological or any other severe (> grade 2) organ toxicity, the dose of innotecan was reduced by 25% for subsequent courses Treatment could be delayed for up to two weeks if symptomatic loxicity persisted and/or the neutrophil count (ANQ was lower than l,000/|il and/or the platelet count lower than 75,000/ul Administration of granulocyte colony-stimulating factor (G-CSF) was recommended in the former group of patients Any patient who required more than 2 weeks for recovery of adverse reactions was taken off the study
Study endpoints and statistical analysis
The primary efficacy end point was response rate, which was evaluated every eight weeks according to WHO standard criteria [9], and confirmed by an independent review committee Secondary efficacy end points included the duration of response, progression-free survival (PFS), and overall survival (OS)
Using standard statistical methods, an optimal two-stage design was employed in the protocol If no CR or PR was noted in the first cohort of 14 patients, a response rate of > 15% could be excluded with 95% Cl and accrual would stop Otherwise, additional patients were enrolled to a final accrual of 38 patients to better estimate efficacy and characterise the toxicity profile This sample size was considered sufficient to estimate 95% CI for the true response rate with a maximum width of 28% The distribution of time to death from the date of study entry was estimated using the Kaplan-Meier product-limit method
Results
Patient characteristics
Between March 1999 and May 2000, a total of 38 patients entered this trial, all of whom were considered evaluable for response and toxicity assessment. The demographic data, sites of metastatic tumour, and prior therapies are listed in Table 1 Twelve patients progressed while receiving or within six months after discontinuing palliative bi-monthly continuous infusional double modulated 5-FU/LV (deGramont regimen) + oxaliplatin, and 26 patients failed first-line treatment with a combination of raltitrexed and oxaliplatin [10] . The median duration off previous chemotherapy was 4.5 (range 1 to 6) months.
A total of 183 courses were administered to the 38 patients. The median number of treatment cycles was 6 (range 2 to 6), and the median duration of follow-up at the time of this analysis was 10 months (range 7 to 21 months) 
Response and survival
The overall objective response rate was 21% for all 38 patients (95% CI: 9.6% to 37.4%). All responses were partial, and their median duration was 5.8 (range 3.5 to 8.0) months. 19 additional patients (50%) showed stabilisation of disease for a median duration of 5.5 (range 3 to 10.5) months, and in 11 patients (29%) the disease progression was not influenced by chemotherapy. The median PFS in all 38 patients was 4 8 months, with a range of 1.5 to 10 5 months There was no significant difference in terms of objective response rate, median PFS and OS between patients who experienced PD while off previous first-line chemotherapy and those who progressed while on previous chemotherapy (defined as truly chemorefractory disease). Objective response rates in these two subsets of patients were 5 of 22 (22.7%) and 3 of 16 (18.8%), respectively (P = 0.911). Similarly, no difference in response activity was noted between the 12 patients who had received 5-FU/LV/oxaliplatin (16 7%) and those (n -26) pretreated with raltitrexed/oxaliplatin (23.1%; P = 0.983). As of December 2000, with a median follow-up duration of 10 (range 7 to 21) months, 17 of all 38 patients entered had died because of PD. Twenty-one patients (55%) are still alive with metastatic disease, of whom 14 had received or currently undergo other cytotoxic therapy. The median survival duration has not been reached yet and was >9.5 (range 2.2 to 18+) months at the time of this report Toxicity All 38 patients, who received a total of 183 courses of therapy, were assessable for toxicity Side effects associated with treatment are listed in Table 2 Haematological toxicity was commonly observed, though it was generally mild to moderate and fully reversible within one week in all patients. Neutropenia occurred in 25 patients (66%), and was grade 4 in only 3 cases (8%). The median nadir of ANCs was 1500/ul (range 230 to 5,480/|il). Thrombocytopenia was relatively uncommon and generally mild; it was noted in a total of six patients (16%), and none of them had WHO grade 3 or 4. Only one patient (3%) developed grade 3 anaemia requiring packed RBC transfusion, whereas mild anaemia was recorded in 24 patients (65%). Five patients developed documented infection, including only one case who required hospitalisation. Among nonhematologic adverse reactions, transient mild to moderate gastrointestinal toxicities were frequently encountered. Grade 3 diarrhoea, however, was noted only in two patients. Other nonmyelosuppressive toxicities included atropine-responsive cholinergic symptoms during administration of lnnotecan in 6 patients (16%), alopecia, which was rated severe in 5 (13%) and mild to moderate in 19 cases (50%), respectively Eleven patients (29%) had at least one treatment delay of one week at some time during therapy, and the total number of delayed courses was 15 (8.2%). The reasons 
for delayed courses were haematological in 10 (neutropenia and/or thrombocytopenia), personal reasons in three, and protracted diarrhoea and the requirement for implantation of a port-a-cath system in one patient each Three patients (8%) had a 25% dose reduction of cytotoxic drugs during treatment according to the study protocol, because of grade 4 neutropenia (n = 2) ± grade 3 diarrhoea (n -2). One patient refused further treatment because of toxic complications (neutropenic sepsis), and two patients warranted early discontinuation for personal reasons after four and five courses, respectively.
Discussion
In agreement with the results of a recently reported randomised pilot phase II pilot study of dose-fractionated lnnotecan in patients with advanced colorectal cancer [6] , and the apparent lack of cross-resistance between the topoisomerase I inhibitor and oxaliplatin, as well as fluoropynmidines/thymidylate synthase inhibitors [11] , an encouraging antitumour activity was noted for this regimen in the present multicenter phase II confirmatory trial The objective response rate was 21% (95% CI 9.6 to 37.4%), and partial responses lasted for a median duration of six months. Together with 19 additional patients experiencing stable disease, tumour progression could be abrogated in more than two thirds of the study population. The therapeutic potential of this dose fractionated regimen is supported by the observed progression-free and overall suvival time of 4.8 and > 9.5 months with 55% of our patients still being alive. Compared to various phase II and III trials using the classical administration schedule of lnnotecan, the tolerance of treatment was remarkable; specifically GI symptoms were rather infrequent and apparently less pronounced. There was no episode of severe vomiting or constipation, and only 2 of 38 patients (5%) experienced severe diarrhoea necessitating a 25% dose reduction. The incidence of these particular severe gastrointestinal symptoms was 14%, 10%, and 22% in both large patient series reported by Cunningham et al. [2] and Rougier et al. [3] . Though this was not a prospectively randomised trial and there might have been differences in pre-treatment characteristics, the low Gl toxicity rate is in agreement with the above mentioned randomised pilot phase II study published byTsavans et al. [6] .
We therefore conclude that dose-fractionated lrinotecan is a safe and rather active second-line treatment option in patients failing or relapsing after oxaliplatin/ fluoropynmidine-based first line combination chemotherapy. The modified treatment schedule seems to be associated with less severe GI toxicity than the classical European three weekly administration schedule. Additional randomised studies to firmly establish this observation and/or to compare it with other strategies to improve the therapeutic index of lnnotecan seem warranted. 
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